Kyowa Kirin published a patient-focused global consensus statement that highlights 12 recommendations for healthcare authorities, policymakers, hospitals, and clinicians to drive positive change for the global cutaneous T-cell lymphoma patient community.
Two clinical trials testing the antibody Zynlonta (loncastuximab tesirine) showed encouraging results in patients with high-risk forms of two blood cancers – follicular lymphoma and marginal zone lymphoma.
